Skip to main content
Clinical Trials/NCT05729425
NCT05729425
Terminated
Not Applicable

Microvessel Ultrasound Imaging of Cutaneous Angiosarcoma

Mayo Clinic1 site in 1 country1 target enrollmentOctober 31, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Skin Angiosarcoma
Sponsor
Mayo Clinic
Enrollment
1
Locations
1
Primary Endpoint
Accuracy of microvessel ultrasound imaging
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

This study evaluates the accuracy of a new ultrasound technology called microvessel imaging for detecting the extent of disease among patients with angiosarcoma of the skin. Microvessel ultrasound imaging uses high frequency waves to visualize vessels in the skin that are not easily seen using other imaging tests.

Detailed Description

PRIMARY OBJECTIVE: I. To determine the accuracy of depicting extent of disease of cutaneous angiosarcoma before and after neoadjuvant treatment compared to clinical photographs, magnetic resonance imaging (MR) or positron emission tomography (PET)/computed tomography (CT) imaging and surgical pathology both on skin biopsies and surgical excision. OUTLINE: Patients undergo microvessel ultrasound imaging on study.

Registry
clinicaltrials.gov
Start Date
October 31, 2022
End Date
August 15, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Diagnosed with cutaneous angiosarcoma of the breast or scalp and scheduled for trimodality therapy
  • Twenty one years of age or older

Exclusion Criteria

  • Unwilling to consent to microvessel ultrasound imaging
  • Younger than 21 years of age

Outcomes

Primary Outcomes

Accuracy of microvessel ultrasound imaging

Time Frame: Through to study completion up to one year

Accuracy with respect to gold standard quantitative measures of disease extent and imaging-based measurements will be evaluated using Lin's concordance correlation coefficient along with 95% confidence intervals (CI's). These will be performed separately pre- and post-treatment. Pearson correlations and 95% CI's between imaging modality measurements will also be estimated to help guide future comparative analyses. Bland-Altman plots will also be generated to visualize agreement.

Study Sites (1)

Loading locations...

Similar Trials